Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Cash Flow for Dividends: NT$0.00 Mil (TTM As of Dec. 2025)


ROCO:7427 Great Novel Therapeutics Biotech & Medicals ROCO:7427
52 GF Score
Price NT$39.75
GF Value NT$25.63
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Great Novel Therapeutics Biotech & Medicals Cash Flow for Dividends?

Great Novel Therapeutics Biotech & Medicals ROCO:7427 +0.51% 52 Cash Flow for Dividends is NT$0.00 Mil as of Dec. 2025. GuruFocus rates ROCO:7427 with a GF Score™ of 52/100 and a GF Value™ of NT$25.63 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Great Novel Therapeutics Biotech & Medicals's cash flow for dividends for the six months ended in Dec. 2025 was NT$0.00 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.00 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Great Novel Therapeutics Biotech & Medicals Cash Flow for Dividends Related Terms

Great Novel Therapeutics Biotech & Medicals Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for Great Novel Therapeutics Biotech & Medicals's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Great Novel Therapeutics Biotech & Medicals Cash Flow for Dividends Chart

Great Novel Therapeutics Biotech & Medicals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow for Dividends
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Great Novel Therapeutics Biotech & Medicals Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ROCO:7427
52GF Score
Great Novel Therapeutics Biotech & Medicals ROCO:7427
Cash Flow for Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Great Novel Therapeutics Biotech & Medicals Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Dividends of NT$0.00 Mil mean?
Great Novel Therapeutics Biotech & Medicals (ROCO:7427) has a Cash Flow for Dividends of NT$0.00 Mil as of Dec. 2025. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Great Novel Therapeutics Biotech & Medicals and its competitors.
Is Great Novel Therapeutics Biotech & Medicals' Cash Flow for Dividends too high?
Great Novel Therapeutics Biotech & Medicals' current Cash Flow for Dividends is NT$0.00 Mil. Overall, Great Novel Therapeutics Biotech & Medicals has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Great Novel Therapeutics Biotech & Medicals' Cash Flow for Dividends compare to VRTX and REGN?
Great Novel Therapeutics Biotech & Medicals' Cash Flow for Dividends of NT$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Biotechnology company?
A good Cash Flow for Dividends depends on the Biotechnology industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Great Novel Therapeutics Biotech & Medicals and its competitors. Great Novel Therapeutics Biotech & Medicals's current Cash Flow for Dividends is NT$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Great Novel Therapeutics Biotech & Medicals stock overvalued right now?
Based on GuruFocus' analysis, Great Novel Therapeutics Biotech & Medicals (ROCO:7427) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$25.63, compared to a current price of NT$39.75 — trading 55.1% above its estimated fair value. The current Cash Flow for Dividends is NT$0.00 Mil. Great Novel Therapeutics Biotech & Medicals' overall GF Score™ is 52/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For Great Novel Therapeutics Biotech & Medicals (ROCO:7427), the current Cash Flow for Dividends is NT$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Overvalued in 2026?

Based on GuruFocus' analysis, Great Novel Therapeutics Biotech & Medicals stock appears to be overvalued. The current stock price of NT$39.75 is trading 55.1% above its estimated GF Value™ of NT$25.63. GuruFocus considers Great Novel Therapeutics Biotech & Medicals to be Significantly Overvalued.

Key valuation signals for ROCO:7427:

  • Cash Flow for Dividends: NT$0.00 Mil
  • GF Value™: NT$25.63 vs. price of NT$39.75 (55.1% above fair value)
  • GF Score™: 52/100 with 6 warning signs

No single metric tells the full story. See the ROCO:7427 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Great Novel Therapeutics Biotech & Medicals Business Description

Address No.3, Park Street, Room WR-06, 17th Floor, Nangang District, Taipei, TWN, 11503
Great Novel Therapeutics Biotech & Medicals focuses on drug development to treat advanced cancer. The new drugs ranging from epigenetic modulators, a combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a developing pipeline. These drugs focus on the field of epigenetics, for the demand of clinical unmet needs in advanced and refractory cancers.
52GF Score

Get the complete analysis for ROCO:7427

Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$39.75
Price
NT$25.63
GF Value